NCT04315558CompletedPhase 2
Revefenacin in Acute Respiratory Insufficiency in COPD
Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO)
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- First submitted
- 16 Mar 2020
- Start date
- 1 Nov 2020
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- University of California, Los Angeles
- Diseases
- COPD
- NCT number
- NCT04315558
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 21
- From 1 Nov 2020 to the primary completion date, 1 Jan 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- For patients taking short- or long-acting muscarinic antagonists (SAMAs or LAMAs) at the time of screening, inability or unwillingness to undergo the SAMA or LAMA washout period (6 hours or 24 hours, respectively) prior to initiating study drug.
- Unwillingness or inability to remain on the study drug with for the duration of the study
Other illness
- Hypersensitivity to muscarinic antagonists
- Presence of ARDS or acute congestive heart failure
- Documented restrictive lung disease or history of interstitial lung disease
- Known history of glaucoma
Lab values
- AST or ALT \> 3 times the upper limit of normal, or other clinically significant acute or chronic liver disease
Other
- Chronic invasive mechanical ventilation via tracheostomy. Patients with tracheostomy alone without chronic mechanical ventilation may be enrolled.
- Expected duration of mechanical ventilation \<24 hours
- Inability to tolerate albuterol
- Lack of documented COPD history
- Unwillingness or inability to have open-label muscarinic antagonists withheld for duration of the study
- Unwillingness or inability to utilize the Puritan-Bennett 980 (PB980) ventilator
- Pulmonary comorbidities such as pneumothorax or pneumomediastinum that, in the opinion of the investigator or clinical team, can pose a risk to subject safety or interfere with the subject's ability to complete the study procedures.
- Actual body weight exceeding 1 kg per centimeter of height
- Pregnancy
- Enrollment in other interventional clinical trial
- Moribund patient not expected to survive \>24 hours
- Decision to withhold life-sustaining treatment, except in those patients committed to full support except cardiopulmonary resuscitation
- Inability to obtain informed consent from patient or legally authorized representative (LAR)
Who the study is looking for
- Adults ≥ 40 years of age
- Acute respiratory failure requiring invasive mechanical ventilation
- Documented history of COPD based on spirometric evidence of FEV1/FVC\<70%
- Smoking history \>10 years (current or prior)
- Invasive mechanical ventilation for \< 96 hours
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ronald Reagan Medical Center at UCLA Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Santa Monica UCLA Coordinator of this site? Confirm its status | Santa Monica | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.